Press releases

Acquisition will bring neuromodulation technology, including a range of neurostimulators, programmable drug pumps and cochlear implants.

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...

Trial assessed the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics.

Company made the announcement at the annual Paris Course on Revascularization, the largest interventional cardiology conference in Europe.

Company expects to announce 30-day results at the 2004 Transcatheter Cardiovascular Therapeutics conference in September.

A replay of the May 26 analyst meeting will also be available. Learn how to tune into the webcast.

Enteryx found equally effective in controlling GERD symptoms in patients previously treated with proton pump inhibitor (PPI) medications at both standard and high dosing.

Company made the announcement at the annual Digestive Disease Week (DDW) conference.

A live webcast and replay of the May 19 conference session will be available.

"The TAXUS launch continues to go extremely well, with sales growing and execution remaining strong," said Jim Tobin, President and Chief Executive Officer.